Nkarta to Participate in Evercore Healthcare Conference
Rhea-AI Summary
Nkarta (Nasdaq: NKTX) will participate in the Evercore 8th Annual Healthcare Conference in Miami on December 4, 2025. Management will appear in a 10:50 a.m. ET fireside chat. A simultaneous webcast will be available on Nkarta’s Investors website, with a replay archived for approximately 90 days.
The presentation focuses on Nkarta’s clinical-stage engineered natural killer (NK) cell therapies for autoimmune diseases and provides an investor access point via live webcast and short-term replay.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NKTX declined 3.87%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, with declines in AGEN (-0.24%), GNLX (-2.44%), MOLN (-1.97%), TIL (-2.14%), while CHRS rose 7.52%, indicating no clear sector-wide driver aligned with NKTX.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Conference participation | Neutral | -3.9% | Announcement of Evercore healthcare conference fireside chat and webcast access. |
| Nov 10 | Earnings and update | Positive | +2.5% | Q3 2025 results with strong cash balance and NKX019 autoimmune program progress. |
| Oct 30 | Investor conferences | Neutral | -0.5% | Participation in November investor conferences with webcast and 90-day replay. |
| Oct 22 | Clinical poster data | Positive | -8.0% | ACR poster showing robust CD19+ B-cell depletion and immune reset signals. |
| Sep 02 | Investor conference | Neutral | -0.9% | Announcement of H.C. Wainwright fireside chat with webcast and replay. |
Most prior news events showed price moves generally aligning with the perceived news tone, though a notable divergence occurred when clinically positive ACR data coincided with a negative price reaction.
Over the past six months, Nkarta has repeatedly highlighted conference participation and clinical progress, including multiple investor events and an ACR Convergence poster on NKX019. Earnings updates in Q3 2025 emphasized $316.5M in cash and investments and funding expectations into 2029. Several conference-related headlines saw modest negative or near-flat reactions, while the ACR data poster, which detailed robust B-cell depletion, was followed by a sharper -7.95% move, suggesting occasional sell-the-news dynamics around positive clinical updates.
Market Pulse Summary
This announcement highlights Nkarta’s participation in the Evercore 8th Annual Healthcare Conference on December 4, 2025, with a 10:50 a.m. ET fireside chat and a webcast replay available for 90 days. It offers an additional investor touchpoint on the company’s engineered NK cell therapy programs. In context of prior conference and clinical updates, investors may focus on clarity around cash usage, progress in autoimmune indications, and the evolution of key programs such as NKX019.
Key Terms
natural killer (NK) cell therapies medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami.
Evercore 8th Annual Healthcare Conference
December 4, 2025
10:50 a.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com
FAQ
When will Nkarta (NKTX) present at the Evercore Healthcare Conference?
How can investors watch Nkarta’s (NKTX) Evercore conference presentation?
Will Nkarta (NKTX) provide a replay of its Evercore presentation and for how long?
What topics will Nkarta (NKTX) likely cover at the Evercore Healthcare Conference?
Is the Evercore 8th Annual Healthcare Conference in person or virtual for Nkarta (NKTX)?
Where on Nkarta’s site will the Evercore webcast be available?
